What is Lyndra Therapeutics?
Founded in 2015 and headquartered in Watertown, Massachusetts, Lyndra Therapeutics is a pharmaceutical manufacturing company dedicated to transforming the patient experience through innovative drug delivery technologies. The company specializes in developing long-acting oral therapies designed to improve medication adherence and therapeutic outcomes. By focusing on the intersection of material science and pharmacology, Lyndra has established itself as a key player in the biotech industry, addressing the persistent challenges of daily pill regimens. Their market position is bolstered by a sophisticated approach to pharmaceutical engineering, which allows for the sustained release of medications, thereby enhancing the efficacy and convenience of chronic disease management.
How much funding has Lyndra Therapeutics raised?
Lyndra Therapeutics has raised a total of $239.5M across 4 funding rounds:
Series A
$23M
Series B
$55M
Series C
$60.5M
Series E
$101M
Series A (2018): $23M with participation from Polaris Partners
Series B (2019): $55M, investors not publicly disclosed
Series C (2021): $60.5M supported by AIG Global Investment Group, Polaris Partners, Limitless Ventures, Invus, and Yipinhong Pharmaceutical Co.
Series E (2023): $101M featuring Polaris Partners, Sarissa Capital Acquisition, and Sun Pharma
Key Investors in Lyndra Therapeutics
Polaris Partners
Polaris Partners is a venture capital firm that specializes in backing transformational companies in the biotech and healthcare sectors, providing deep operational expertise and scientific guidance.
Sarissa Capital Acquisition
Sarissa Capital Acquisition Corp. is a specialized investment entity focused on facilitating business combinations, mergers, and strategic asset acquisitions within the broader market.
Sun Pharma
Sun Pharma is a global specialty generic pharmaceutical company headquartered in Mumbai, India, known for its extensive manufacturing and distribution of pharmaceutical formulations.
What's next for Lyndra Therapeutics?
With the successful closure of its latest funding round, Lyndra Therapeutics is poised to enter a pivotal phase of its corporate lifecycle. The strategic allocation of these funds will likely prioritize the scaling of manufacturing capabilities to meet anticipated demand for its lead therapeutic candidates. Furthermore, the company is expected to deepen its clinical development efforts, moving toward regulatory milestones that will validate its platform's safety and efficacy at scale. As the firm continues to attract high-caliber institutional support, the focus will shift toward commercial strategy and the potential for strategic partnerships that can amplify its reach in global healthcare markets. The integration of these resources will be instrumental in maintaining the company's competitive edge as it navigates the complexities of the pharmaceutical regulatory environment.
See full Lyndra Therapeutics company page
